The global lung cancer therapy market is expected to grow at a CAGR of 5.5% from 2021 to 2030. The market is driven by the increasing incidence of lung cancer, which is the leading cause of cancer-related deaths worldwide. Lung cancer accounts for about 1 in 3 cases of all cancers and 1 in 5 deaths due to cancer globally. The high incidence and mortality rates are attributed to the lack of early detection methods, which leads to late diagnosis and poor prognosis for patients with advanced stage disease. Radiation therapy accounted for the largest share in 2018 owing to its effectiveness as a treatment modality for localized tumors, low side effects profile, and availability as an outpatient procedure. Chemotherapy was also among the top segments owing to its efficacy against metastatic tumors that have spread beyond their original site or organ system; however, it has been associated with severe side effects such as nausea, vomiting, hair loss, fatigue etc, which limits its use in some cases. Targeted therapies are expected to grow at a CAGR of 7% during 2019-2030 owing mainly due their ability to target specific molecular pathways involved in tumor growth and progression without affecting other cells or tissues; this makes them more effective than conventional chemotherapy drugs that affect healthy cells too leading them being less effective against advanced stage cancers where there are fewer healthy cells left unaffected by tumor growths.
Industry Growth Insights published a new data on “Lung Cancer Therapy Market”. The research report is titled “Lung Cancer Therapy Market research by Types (Radiation Therapy, Chemotherapy, Targeted Therapies, Immunotherapy, Lung Cancer Therap), By Applications (Hospitals, Clinics, Other), By Players/Companies GlaxoSmithKline, Menarini, Pfizer, Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Abbott, Akebia Therapeutics, Agennix AG, Lung Cancer Therap”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Lung Cancer Therapy Market Research Report
By Type
Radiation Therapy, Chemotherapy, Targeted Therapies, Immunotherapy, Lung Cancer Therap
By Application
Hospitals, Clinics, Other
By Companies
GlaxoSmithKline, Menarini, Pfizer, Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Abbott, Akebia Therapeutics, Agennix AG, Lung Cancer Therap
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Lung Cancer Therapy Market Report Segments:
The global Lung Cancer Therapy market is segmented on the basis of:
Types
Radiation Therapy, Chemotherapy, Targeted Therapies, Immunotherapy, Lung Cancer Therap
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Menarini
- Pfizer
- Roche
- Merck
- AstraZeneca
- Sanofi-Aventis
- Eli Lilly and Company
- Abbott
- Akebia Therapeutics
- Agennix AG
- Lung Cancer Therap
Highlights of The Lung Cancer Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Radiation Therapy
- Chemotherapy
- Targeted Therapies
- Immunotherapy
- Lung Cancer Therap
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lung Cancer Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lung cancer therapy is the use of medications and/or surgery to treat lung cancer. Treatment options include chemotherapy, radiation therapy, and surgery.
Some of the major players in the lung cancer therapy market are GlaxoSmithKline, Menarini, Pfizer, Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Abbott, Akebia Therapeutics, Agennix AG, Lung Cancer Therap.
The lung cancer therapy market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lung Cancer Therapy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Lung Cancer Therapy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Lung Cancer Therapy Market - Supply Chain
4.5. Global Lung Cancer Therapy Market Forecast
4.5.1. Lung Cancer Therapy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Lung Cancer Therapy Market Size (000 Units) and Y-o-Y Growth
4.5.3. Lung Cancer Therapy Market Absolute $ Opportunity
5. Global Lung Cancer Therapy Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Lung Cancer Therapy Market Size and Volume Forecast by Type
5.3.1. Radiation Therapy
5.3.2. Chemotherapy
5.3.3. Targeted Therapies
5.3.4. Immunotherapy
5.3.5. Lung Cancer Therap
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Lung Cancer Therapy Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Lung Cancer Therapy Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Lung Cancer Therapy Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Lung Cancer Therapy Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Lung Cancer Therapy Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Lung Cancer Therapy Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Lung Cancer Therapy Demand Share Forecast, 2019-2026
9. North America Lung Cancer Therapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Lung Cancer Therapy Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Lung Cancer Therapy Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Lung Cancer Therapy Market Size and Volume Forecast by Type
9.7.1. Radiation Therapy
9.7.2. Chemotherapy
9.7.3. Targeted Therapies
9.7.4. Immunotherapy
9.7.5. Lung Cancer Therap
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Lung Cancer Therapy Demand Share Forecast, 2019-2026
10. Latin America Lung Cancer Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Lung Cancer Therapy Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Lung Cancer Therapy Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Lung Cancer Therapy Market Size and Volume Forecast by Type
10.7.1. Radiation Therapy
10.7.2. Chemotherapy
10.7.3. Targeted Therapies
10.7.4. Immunotherapy
10.7.5. Lung Cancer Therap
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Lung Cancer Therapy Demand Share Forecast, 2019-2026
11. Europe Lung Cancer Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Lung Cancer Therapy Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Lung Cancer Therapy Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Lung Cancer Therapy Market Size and Volume Forecast by Type
11.7.1. Radiation Therapy
11.7.2. Chemotherapy
11.7.3. Targeted Therapies
11.7.4. Immunotherapy
11.7.5. Lung Cancer Therap
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Lung Cancer Therapy Demand Share, 2019-2026
12. Asia Pacific Lung Cancer Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Lung Cancer Therapy Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Lung Cancer Therapy Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Lung Cancer Therapy Market Size and Volume Forecast by Type
12.7.1. Radiation Therapy
12.7.2. Chemotherapy
12.7.3. Targeted Therapies
12.7.4. Immunotherapy
12.7.5. Lung Cancer Therap
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Lung Cancer Therapy Demand Share, 2019-2026
13. Middle East & Africa Lung Cancer Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Lung Cancer Therapy Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Lung Cancer Therapy Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Lung Cancer Therapy Market Size and Volume Forecast by Type
13.7.1. Radiation Therapy
13.7.2. Chemotherapy
13.7.3. Targeted Therapies
13.7.4. Immunotherapy
13.7.5. Lung Cancer Therap
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Lung Cancer Therapy Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Lung Cancer Therapy Market: Market Share Analysis
14.2. Lung Cancer Therapy Distributors and Customers
14.3. Lung Cancer Therapy Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Menarini
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Merck
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. AstraZeneca
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sanofi-Aventis
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly and Company
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Abbott
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Akebia Therapeutics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Agennix AG
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Lung Cancer Therap
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook